Epivision has developed a breakthrough, epigenetic liquid biopsy platform that enables precise disease detection at the earliest stages. Epivision promises to improve early detection, diagnosis, and monitoring of multiple cancer types. Our initial focus is on solving critical, immediate pain points in breast cancer management with a single, minimally invasive blood draw (<1mL plasma), validated across all breast densities.